Glucocorticoid receptors in lung cancer: new perspectives

Kerryn M Taylor¹, David W Ray² and Paula Sommer¹

¹Division of Genetics, School of Life Sciences, University of KwaZulu-Natal, Durban, South Africa
²Manchester Centre for Nuclear Hormone Research and Disease, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester, United Kingdom

Abstract

Proper expression of the glucocorticoid receptor (GR) plays an essential role in the development of the lung. GR expression and signalling in the lung is manipulated by administration of synthetic glucocorticoids (Gcs) for the treatment of neonatal, childhood and adult lung diseases. In lung cancers, Gcs are also commonly used as co-treatment during chemotherapy. This review summarises the effect of Gc monotherapy and co-therapy on lung cancers in vitro, in mouse models of lung cancer, in xenograft, ex vivo and in vivo. The disparity between the effects of pre-clinical and in vivo Gc therapy is commented on in light of the recent discovery of GR as a novel tumour suppressor gene.

Lung cancer

Lung cancers are the leading cause of cancer-related deaths worldwide and are thus a major therapeutic burden. While the incidence of lung cancer has plateaued in the developed world, it continues to increase in the developing world. Being predominantly caused by smoking, lung cancers have a poor prognosis with a combined 5-year survival rate of less than 20% (Torre et al. 2015). Lung cancers show heterogeneity and are therefore classified into two major groups, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLCs account for over 80% of all lung cancers and include adenocarcinomas, squamous cell carcinomas and bronchioalveolar and large cell carcinomas. The remaining 15–20% of lung cancers show features of neuroendocrine differentiation and are classified as SCLC. Bronchioalveolar stem cells are postulated to play a role in NSCLC tumourigenesis, while a rare population of neuroendocrine cells or less differentiated cells are thought to be the progenitor cells for SCLC. However, the cell/s of origin for these different lung cancers have not been definitively described with recent studies revealing remarkable plasticity in the regenerative powers of various lung cell types, further complicating the matter (Semenova et al. 2015).

The driver mutations for NSCLC particularly have been well described, and mutation testing can be used for patient stratification and prescription of targeted therapy (Pao & Girard 2011).

The glucocorticoid receptor

Glucocorticoids (Gcs) are a class of steroid hormones that function to maintain homeostasis. The effects of Gcs are mediated by the ubiquitously expressed glucocorticoid receptor (GR), an intracellular ligand-activated transcription factor and member of the nuclear receptor superfamily. The GR is encoded by a single copy gene on chromosome 5, spanning an area of 110 kb (Turner & Muller 2005, Zhou & Cidlowski 2005). There are numerous transcriptional and translational isoforms of the GR.
The precise reasons for this are not clearly delineated, but the tissue-specific expression of these isoforms as well as their subtle differences in function suggest that these may be a mechanism to generate the massive signalling diversity exhibited by the GR (Oakley & Cidlowski 2011). The GR is a modular protein, organised into three major functional domains: the N-terminal domain, DNA-binding domain and C-terminal ligand-binding domain (Cruz-Topete & Cidlowski 2015). Unliganded GR resides in the cytosol associated with a macromolecular complex of chaperone and other proteins. Upon Gc binding, the GR becomes hyperphosphorylated, causing conformational changes in the GR resulting in dissociation of the receptor from the inactive, cytoplasmic multiprotein complex. The hyperphosphorylated receptor subsequently dimerises and migrates to the nucleus, where the GR can bind to DNA directly to regulate transcription, tether to other DNA-bound transcription factors or bind directly to DNA and interact with neighbouring transcription factors. GR signalling can also mediate rapid, non-genomic effects, as well as modify chromatin to stimulate or suppress the expression of a plethora of target genes (Cruz-Topete & Cidlowski 2015). The most well-described effects of Gc signalling are their anti-inflammatory properties, where liganded GR physically interacts with nuclear factor-κB (NF-κB) and AP-1, preventing their induction of pro-inflammatory genes.

The role of the GR in lung development

Development of the lung, characterised by branching morphogenesis and reciprocal endodermal–mesodermal interactions, begins at ~embryonic day (E) 9.5 in mouse and ~28 days in human with the formation of primary lung buds. These buds extend into the mesenchyme and begin the process of branching morphogenesis. The initial stage of branching morphogenesis, the ‘pseudoglandular’ stage, is characterized by proliferation and growth resulting in the formation of tree-like structures ending in terminal tubules. In the following stages, the ‘canicular’ stage (E16.5–E17.5) and the ‘saccular’ stage (E17.5–postnatal P5), these tubules begin the process of differentiation into alveoli precursors, the functional units for gaseous exchange. Progression from the pseudoglandular stage is accompanied by a surge in Gc secretion and an increase in the expression of the GR in the lung, suggesting that the GR plays a role in organ maturation. The mesoderm surrounding the lung buds plays an important role in development as a source of spatio-temporal signals driving differentiation (Morrisey & Hogan 2010).

The presence of a functional GR is essential for normal lung development. The precise signalling mechanisms are not understood but it is accepted that Gc exposure acts to expand the proximal and distal airways and thin the intervening mesenchymal tissue, allowing for optimal gaseous exchange. Null and conditional Gr−knockout mice die at or just after birth, displaying severe lung abnormalities and respiratory failure (Cole et al. 1995, Tronche et al. 1999, Brewer et al. 2002). The lungs of these Gr−knockouts appear normal until E15.5 but subsequently show hypercellularity, with the severity of the phenotype modulated by genetic background. The observed hypercellularity is due to an increased proliferation rate rather than a lack of Gc-induced apoptosis (Bird et al. 2015). This onset coincides with the Gc surge which occurs at ~E14.5 in mice, towards the end of the pseudoglandular stage. In humans, the Gc surge occurs just before birth (Rog-Zielinska et al. 2014). GR activity in the mesenchymal compartment of the lung is currently thought to drive the correct development of the lung. Specific ablation of the GR in mesenchymal cells has been created by crossing GRfl/fl with mice that express Cre et al. 2015). This onset coincides with the Gc surge which occurs at ~E14.5 in mice, towards the end of the pseudoglandular stage. In humans, the Gc surge occurs just before birth (Rog-Zielinska et al. 2014). GR deletion specific to the mesenchyme was also accomplished using other mesenchymal markers, Dermo1/Twist2 (Li et al. 2013, Bird et al. 2014). These mice show similar effects although varying in severity. Bird et al. (2015) suggest that the variation in lethality in these latter models is possibly due to incomplete GR deletion in the mesenchyme in these two models. An important consequence of this observation points to the necessity of a threshold level of GR in the mesenchyme necessary for proper lung development.

Gc therapy and the lung

Since their discovery more than seven decades ago, Gcs remain among the most widely prescribed drugs worldwide. Inhaled corticosteroids are commonly used to treat asthma based on their potent anti-inflammatory action. As the landmark publication showing that antenatal steroids markedly reduce respiratory distress and neonatal mortality in infants born before 34 weeks of gestation
of retinoblastoma (Rb) phosphorylation, preventing progression from G1 to S phase (Greenberg et al. 2002).

In contrast, however, to the majority of published studies, dexamethasone enhanced the proliferation of the Calu-6 cell line (described as a pulmonary NSCLC cell line) both in vitro and in xenograft (Gundisch et al. 2012) suggesting that the specific lung cancer type as well as GR content of the cells may play a role in response to Gcs.

Liang et al. (2014) showed, using A549 cells (with wild-type p53) and SK-MES-1 (squamous lung carcinoma cells that are p53 deficient), that the anti-proliferative effect of synthetic Gcs requires functional p53. p53 expression has also been shown to be necessary for Gc-mediated cell cycle arrest and apoptosis in MC3T3-E1 (osteoblast) cells (Li et al. 2012). p53 acts as a general inhibitor of inflammation, antagonising NF-κB. Although the precise mechanism is unknown, p53 is thought to be required for liganded GR repression of NF-κB (Murphy et al. 2011). NF-κB is constitutively active in most cancers and many lung cancers have mutations in p53 (Gudkov et al. 2011). This may offer a possible explanation as to why Gcs cannot significantly reduce inflammation in tumour cells. In p53-null H1299 cells (a lung adenocarcinoma cell line) that also express low levels of the GR, dexamethasone had no effect on cell proliferation; however, the inhibitory effects on proliferation were restored by restoring GR expression ectopically in these cells. High levels of GR in this context may, therefore, be sufficient to overcome the lack of p53 (Patki et al. 2014).

These in vitro studies predominantly show that Gc treatment has growth-inhibitory effects on NSCLC cell lines, most of which are GR abundant, and, to a lesser extent, that p53 plays a role in mediating the dexamethasone growth-suppressive effects in vitro.

In chemically induced lung cancer tumours Lung tumours can be chemically induced in mice by treatment with cigarette smoke, cigarette smoke carcinogens such as nicotine-derived nitrosamine ketone (NNK) or benzo(a)pyrene (BP), or classic carcinogens such as vinyl carbamate. The majority of tumours produced by these methods are classified as adenomas or adenocarcinomas (NSCLCs) (Meuwissen & Berns 2005). In strain H mice with cigarette-smoking-induced tumours, the administration of budesonide upon weaning or after cessation of exposure to cigarette smoke decreased both the incidence and multiplicity of lung tumours (Balansky et al. 2010). A potential mechanism for this was revealed in an in vitro
Figure 1
Summary of the effects of Gc monotherapy (A) and co-treatment (B) on lung cancer in \textit{in vitro}, in xenograft, chemically-induced mouse models and \textit{in vivo} situations. Dex, dexamethasone; Bud, budesonide; COPD, chronic obstructive pulmonary disease.
Glucocorticoid receptors in lung cancer

In vitro These growth-delaying effects seen in controlled, genetically homogenous cell lines in vitro and in xenograft experiments do not appear to be translated to the genetically heterogenous in vivo situation. Early case series and randomised controlled trials performed in the 1960s on patients with advanced lung cancer (summarised in (Keith 2008)) showed that Gc monotherapy on lung cancer patients had no survival benefits.

More recent in vivo studies primarily focus on the effects of inhaled Gc treatment in patients with different manifestations of lung inflammation. Chronic inflammation plays a crucial role in tumourigenesis and such inflammation may be present in pre-cancerous individuals.

A randomised, double blind, placebo controlled phase IIb trial was performed to determine the effects of inhaled budesonide in smokers with bronchial dysplasia. Patients were selected for their high risk of lung cancer and given either budesonide or placebo for 6 months. Despite the evidence in xenograft, there was no difference between the budesonide and placebo groups. The authors postulate that the discrepancy may lie in that the xenograft models are primarily adenocarcinoma, while the patients in this study were primarily at risk for squamous cell carcinoma (Lam et al. 2004).

An observational epidemiological study performed on data from patients diagnosed with chronic obstructive pulmonary disease (COPD) found that inhaled corticosteroid use resulted in a lower incidence of lung cancer (Parimon et al. 2007). COPD is a risk factor for lung cancer because of its association with smoking and inflammation.

Clinical trials have been performed to determine the effects of inhaled Gcs on patients with lung nodules. More subjects had a decrease and fewer had an increase in the number of nodules detected on chest CT (although this trend did not reach statistical significance) or Gcs had no effect on the formation of new lesions (van den Berg et al. 2008). However, pre-existing non-solid or partially solid nodules that have a greater chance of progressing to adenocarcinoma decreased in size after treatment (Veronesi et al. 2011).

The results of these pre-cancerous studies are conflicting with inhaled budesonide having either no survival effect, or showing a slight decrease in either the incidence of lung cancer (although observational) or a trend towards a decrease in new nodule formation, or a decrease in existing nodule size.

In xenograft models of lung cancer In xenografts created with A549 cells, a combination treatment of drugs thought to act on the tumour microenvironment (dipyridamole, bestatin and dexamethasone) significantly reduced tumour weight (Liu et al. 2014), while in the Lewis lung-tumour bearing mice, treatment with dexamethasone decreased tumour volume (Geng et al. 2014).

Thus, the evidence from both in vitro and in xenograft studies and mouse models suggests that Gc monotherapy can have a negative effect on tumour growth.
The effects of Gc treatment on SCLC

**In vitro** The effects of Gcs on SCLC cell lines are not well described. Earlier studies showed that SCLC cell lines are generally Gc resistant due to mutations in the GR (Ray et al. 1994, 1996). Later exploration of this resistance revealed that SCLC cell lines also contain reduced GR content compared to NSCLC (Sommer et al. 2007, Kay et al. 2011, Schlossmacher et al. 2013). Furthermore, re-expression by retroviral over-expression both in vitro and in xenograft resulted in apoptotic induction, prompting us to postulate that loss of GR expression may play a role in tumourigenesis and to speculate that a threshold level of the GR is required for GR activity in SCLC cells (Sommer et al. 2007, 2010). We later showed that the reduction in GR is due to silencing by methylation (Kay et al. 2011, Singh et al. 2014). Unpublished preliminary data show that, although heterogenous, there are distinct differences in the methylation profile of the GR promoter in patients diagnosed with NSCLC and SCLC.

**In xenograft** In contrast to the chemically induced mouse models of lung cancer and the xenograft studies described in the previous section which are predominantly NSCLC, in a model of SCLC (mice harbouring mutations in both Rb1 and p53), budesonide treatment did not have a statistically significant effect on tumour growth. This is possibly due to the low levels of GR in SCLC but also may be compounded by the loss of p53 (Wang et al. 2009).

The effect of Gcs when used as co-treatment in lung cancer

The use of Gcs as co-treatment in chemotherapy has long been under debate in pre-clinical studies (reviewed in Herr et al. 2007). A summary of the effects of Gcs as co-treatment in lung cancers is presented in Table 1 and depicted in Fig. 1B.

**In vitro**

*In vitro* studies using a variety of different NSCLC cell lines show that dexamethasone treatment affects sensitivity to pemetrexed or cisplatin chemotherapy (Herr et al. 2003, Gassler et al. 2005, Ge et al. 2012, Patki et al. 2014). The importance of sufficient GR is highlighted as dexamethasone effects are not dependent on p53 but rather dependent on the GR status, as dexamethasone treatment did not influence pemetrexed effects on H1299 cells (which contain low levels of GRα) (Patki et al. 2014). Lack of sensitivity to pemetrexed action was restored in H1299 cells transduced with exogenous GR and pre-treated with dexamethasone for 48 h (Patki et al. 2014). Dexamethasone pre-treatment for 24 h also decreased sensitivity towards cisplatin in GR-containing H460 NSCLC cells (Lu et al. 2005).

**In xenograft**

Dexamethasone treatment prevented tumour growth inhibitory effects of cisplatin in xenografts created with A549 (Ge et al. 2012) and P693 (squamous lung cancer) cells (Herr et al. 2003). Both A549 and P693 cells are known to express high levels of GR, and apoptosis sensitivity was partially restored *in vitro* by treatment with the GR antagonist, RU486 (Herr et al. 2003), suggesting a direct role for GR activity in interfering with cisplatin action by disruption of death signalling pathways.

Most chemotherapy agents are toxic and suppress bone marrow leading to neutropenia or thrombocytopenia. Dexamethasone is known to affect the tumour microenvironment by reducing tumour interstitial fluid and may have haemoprotective activity. In a study aimed at principally addressing these chemotherapy side effects, murine xenografts were created with A549 (p53 wild-type, GR-rich) and H1299 (p53 null with low GR content) cells. Pre-treatment with dexamethasone (0.1 mg/day/mouse for 5 days) increased the therapeutic effect of carboplatin and gemcitabine for A549 xenografts, and gemcitabine alone for H1299 xenografts. Dexamethasone pre-treatment alone did not have a significant effect on tumour growth but did, interestingly, increase tumour gemcitabine concentrations (Wang et al. 2004). This study differs from the other xenograft studies in that it uses pre-treatment rather than co-treatment and also uses an unusually high dose of dexamethasone.

**Ex vivo**

*Ex vivo* studies, where cells were grown from biopsy tissue material from adenocarcinoma and squamous carcinoma (all at least T2-4 but M0) and one SCLC (T2M0) biopsy, cisplatin and gemcitabine treatment reduced cell viability, but co-treatment with dexamethasone reduced this growth inhibition effect (Gassler et al. 2005).
### Table 1  Summary of the effects of Gcs when used as co-treatment during chemotherapy of lung cancers.

<table>
<thead>
<tr>
<th>Lung cancer type</th>
<th>Classification/ subtype</th>
<th>Study type</th>
<th>Treatment</th>
<th>Finding</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSCLC</td>
<td>Non-squamous-cell cancer cell lines (A549, H1299, H358, H226, H460, H1650, ADLC-5SM2 and H292 cells)</td>
<td>✓ In vitro, In xenograft, Ex vivo In vivo</td>
<td>Co-treatment with 100 nM Dex for 48 h</td>
<td>Reduces chemotherapeutic effect of pemetrexed in GR-rich A549 cells but not in GR-poor H1299 cells</td>
<td>Patki et al. (2014)</td>
</tr>
<tr>
<td>NSCLC</td>
<td>H460</td>
<td>✓</td>
<td>Pre-treatment with 1 mmol/L Dex for 24 h followed by cisplatin</td>
<td>Reduces chemotherapeutic effect of cisplatin</td>
<td>Lu et al. (2005)</td>
</tr>
<tr>
<td>NSCLC</td>
<td>A549, NCI-H292 and NCI-H1299 cells, A549 cells</td>
<td>✓</td>
<td>Co-treatment with 1 µM Dex for 48 h</td>
<td>Reduces chemotherapeutic effect of cisplatin</td>
<td>Ge et al. (2012)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>✓</td>
<td>Co-treatment of 0.2 mg/kg Dex on the day before, day of and day after cisplatin injection when tumours reached 200 mm³</td>
<td>Reduces chemotherapeutic effect of cisplatin</td>
<td></td>
</tr>
<tr>
<td>NSCLC</td>
<td>P693 cells (squamous carcinoma cells)</td>
<td>✓</td>
<td>Co-treatment of 0.28 mg/L Dex along with cisplatin treatment when tumours reached 500 mm³</td>
<td>Reduces chemotherapeutic effect of cisplatin</td>
<td>Herr et al. (2003)</td>
</tr>
<tr>
<td>NSCLC</td>
<td>A549 (p53 wt) cells</td>
<td>✓</td>
<td>Pre-treatment with 0.1 mg/day/mouse Dex for 5 days followed by carboplatin or gemcitabine</td>
<td>Enhances chemotherapeutic effect of carboplatin and gemcitabine in GR-rich, p53 wild-type A549 cells</td>
<td>Wang et al. (2004)</td>
</tr>
<tr>
<td></td>
<td>H1299 (p53 null) cells</td>
<td>✓</td>
<td>Pre-treatment with 0.1 – 10 µM Dex for 24 h followed by cisplatin or gemcitabine</td>
<td>Heterogeneity in data but overall reduction in chemotherapeutic effect of cisplatin or gemcitabine</td>
<td>Gassler et al. (2005)</td>
</tr>
<tr>
<td>NSCLC and one SCLC</td>
<td>Cells grown from biopsy material from five adenocarcinomas and four squamous cell carcinomas (T2-4, M0) and 1 SCLC (T2M0) biopsy</td>
<td>✓</td>
<td>Pre-treatment with 0.1 – 10 µM Dex for 24 h followed by cisplatin or gemcitabine</td>
<td>Heterogeneity in data but overall reduction in chemotherapeutic effect of cisplatin or gemcitabine</td>
<td></td>
</tr>
<tr>
<td>SCLC</td>
<td>Metastatic</td>
<td>✓</td>
<td>Corticosteroid co-treatment (for peri-tumoural oedema only) with teniposide</td>
<td>Corticosteroid co-treatment appeared to reduce chemotherapeutic effect of teniposide</td>
<td>Postmus et al. (1995)</td>
</tr>
<tr>
<td>NSCLC and SCLC</td>
<td>Metastatic</td>
<td>✓</td>
<td>Cyclophosphamide alone or in combination with prednisolone</td>
<td>Prednisolone co-treatment appeared to reduce patient survival</td>
<td>Thatcher et al. (1982)</td>
</tr>
<tr>
<td>NSCLC</td>
<td>Advanced</td>
<td>✓</td>
<td>Pre-treatment with 8 or 16 mg Dex twice a day, 4 days before and on day of chemotherapy</td>
<td>Pre-treatment with high doses reduces haematological toxicity</td>
<td>Leggas et al. (2009)</td>
</tr>
<tr>
<td>NSCLC</td>
<td>Stage IV</td>
<td>✓</td>
<td>Pre-treatment with 16 mg Dex twice a day, 4 days before and on Days 1 and 8 of chemotherapy</td>
<td>Pre-treatment with high doses reduces haematological toxicity</td>
<td>Rinehart et al. (2013)</td>
</tr>
</tbody>
</table>
The dexamethasone effects were heterogenous but still showed partial protection against cisplatin-induced death, prompting the authors to suggest the use of non-steroidal agents for management of nausea.

In vivo

In 1982, a study was performed to determine whether high doses of cyclophosphamide could be effective at prolonging life span in patients with metastatic NSCLC and SCLC. Since cyclophosphamides cause bone marrow suppression, the study tested whether addition of prednisolone to the regimen could ameliorate toxicity. The addition of prednisolone did not improve the therapeutic efficacy of cyclophosphamide nor did it ameliorate toxicity. The study did show, however, that NSCLC patients treated with cyclophosphamide alone lived significantly longer than patients treated with cyclophosphamide plus prednisolone. Although not commented on in this study, this suggests that prednisolone administration in NSCLC may interfere with chemotherapy (Thatcher et al. 1982).

Similar negative effects on chemotherapy were reported in a phase II study (Postmus et al. 1995). Although not the primary objective, in a study to determine the efficacy of teniposide on patients diagnosed with SCLC that had metastasised to the brain, corticosteroid co-treatment (administered in patients with peritumoural oedema only) resulted in a significantly reduced chemotherapy response rate, resulting in the authors cautioning the use of corticosteroids during chemotherapy of brain metastases. Interestingly, in a phase III follow on of this trial, the effects of Gc were not tested (Postmus et al. 2000).

These earlier studies, coupled with in vitro and in xenograft data, show that dexamethasone treatment appears to counter the effects of the chemotherapy agents on solid tumours, prompting a viewpoint in the Lancet in 2002 cautioning use of corticosteroid co-treatment (Rutz 2002). Although primarily focused on prostate cancers, a similar stance was taken in a review in 2007 (Herr et al. 2007); a systematic meta-analysis in 2008 concluded that both Gc monotherapy and co-therapy had a deleterious effect on lung cancer (Keith 2008).

Despite this evidence, there are no more recently published data from clinical trials aimed primarily at determining the effects of Gc treatment on lung cancer. More recent studies have focused on the use of Gcs to ameliorate the toxic effects (such as haematological toxicity) of chemotherapy. In a phase I/II trial to determine the optimal dose of dexamethasone pre-treatment to reduce chemo-induced haematopoetic toxicity, patients with NSCLC stage 3B/4 were given 8 or 16 mg dexamethasone 4 days before and on the day of chemotherapy. Dexamethasone treatment was shown to reduce haematological toxicity (assessed by nadir absolute granulocyte count (AGC) and platelet counts). The primary and secondary end points of the study were not designed to determine the effect of dexamethasone co-treatment with carboplatin and gemcitabine. For its favourable effects on preventing toxicity, the authors promote the use of high doses of dexamethasone pre-treatment (Leggas et al. 2009).

Based on these findings this same research group performed a randomised phase II trial of carboplatin and gemcitabine with or without dexamethasone in untreated patients with Stage IV NSCLC. The protocol was designed to test the hypothesis that dexamethasone pre-treatment reduced toxicity of chemotherapy in patients with Stage IV NSCLC. The primary endpoint of the study was haematological toxicity. Dexamethasone treatment reduced haematological toxicity but had no effect on non-haematological toxicity or quality of life. Although the authors suggest that dexamethasone enhances the chemotherapeutic response, overall dexamethasone treatment did not significantly affect survival (Rinehart et al. 2013).

In more recent studies comparing chemotherapy agents, dexamethasone is given to all patient groups (Schmid-Bindert et al. 2013, Xu et al. 2015) and has, along with other anti-emetic agents, been recommended as co-treatment for patients undergoing cisplatin treatment (Kitazaki et al. 2015).

Pre-clinical data show predominantly that dexamethasone co-treatment has a negative effect on chemotherapy. These pre-clinical data are predominantly collected in genetically homogenous cell lines and inbred animal models where both GR content and p53 are known. Early studies suggest that this negative effect may be extended to a genetically heterogenous patient population; however, this has not been explored with newer studies focusing primarily on the positive effects of dexamethasone in reducing inflammation, alleviating allergic response and preventing nausea.

The GR as a TSG for lung cancer

In SCLC, we have shown that the expression of the GR exerts an anti-survival effect on SCLC cells in vitro and...
in xenograft (Sommer et al. 2007, 2010), suggesting that silencing of the GR plays a role in SCLC tumourgenesis. Our work showed that SCLC cell lines contained reduced GR transcripts when compared to NSCLC cell lines. A recent report has extended these observations to show that the GR appears downregulated in many cancers including liver, prostate, colon and breast (Matthews et al. 2015). In SCLC, GR downregulation occurs due to methylation of the GR promoter (Kay et al. 2011, Singh et al. 2014). Others have shown that in ovarian cancer, BRCA1 is a potential regulator of the GR, possibly through phosphorylation of Ser211 and entry of GR into the nucleus. GR is thus decreased in BRCA1-mutated ovarian cancer (Fang et al. 2014).

The GR promoter is similarly silenced in gastric and colorectal cancers suggesting that GR silencing may play a global role in tumour development. GR expression was also shown to be decreased in breast cancer patients compared to non-malignant tissue along with frequent GR promoter methylation (Nesset et al. 2014). In breast cancer, unliganded GR interacts with BRCA1. Thus, loss of GR from the BRCA1 promoter as a result of Gc stimulation leads to reduced BRCA1 expression, which may contribute to the development of sporadic breast tumours which do not show mutations in BRCA1 (Ritter et al. 2012). Decreased GR expression, therefore, appears to be a ubiquitous and important event, leading to the suggestion that the GR is a TSG in the breast as high GR expression is correlated with anti-proliferative signalling. Importantly, genetic heterogeneity influences this effect as loss of GR has a better outcome in ER− breast cancer but a poorer outcome in ER+ breast cancer, indicating that GR effects in breast cancer may be tumour sub-type dependent (Ritter et al. 2012). The GR has also been postulated to act as a tumour suppressor in skin and prostate cancers (Chebotaev et al. 2007, Yemelyanov et al. 2007).

A recent study has definitively shown that the GR is an authentic TSG (Matthews et al. 2015). Aged GR haploinsufficient mice display increased numbers of microtumours and DNA damage compared to their wild-type counterparts and, in cultured B lymphocytes from patients with GR haploinsufficiency, the chromosome complement was significantly lower than from unaffected family members. The report elegantly demonstrates a novel, non-transcriptional role for the GR in mitosis where the GR localises to the spindle centrosome during metaphase and anaphase of mitosis. Here, the GR is phosphorylated at multiple sites by Aurora A (Aurka), a kinase associated with the centrosome whose presence is vital for mitotic progression. Loss of the GR at the spindle resulted in a delayed metaphase and transition to anaphase, thought to be caused by errors in chromosome segregation. Rescue from this phenotype was prevented by the loss of the ligand-binding domain of the GR; however, ligand binding does not appear to be required for chromosome segregation suggesting a role for the domain in protein–protein interaction. These data point to an important role for the GR regulating mitotic progression. GR loss results in errors in chromosome segregation leading to aneuploidy and eventually carcinogenesis (Matthews et al. 2015).

Conclusions

Expression of the GR is intimately linked to the lung. Sufficient GR levels are required for proper lung development and its developmental and post-developmental activity in the lung has been exploited for the treatment of neonatal, childhood and adult lung disorders.

Gc monotherapy of NSCLC cell lines and xenografts predominantly shows that Gc treatment is growth inhibitory. These growth-inhibitory effects are limited by low levels of the GR and mutations in p53. In murine models of chemically induced lung cancers, Gc treatment shows efficacy as an anti-tumour agent when administered prior to exposure and during exposure, but efficacy is reduced when administered at late-stage cancer. Once again, growth-limiting effects are dependent on the presence of functional GR and p53. This is evidenced in SCLC cell lines and xenografts which are generally Gc resistant due to low levels of the GR. In these studies, the growth-inhibitory effects of the GR are thought to be due to growth arrest mediated by a wide variety of different mechanisms including GR inhibition of cyclin D and augmentation of p21 and p27 expression (Rogatsky et al. 1997). The effect of Gc monotherapy in vivo is conflicting. Not surprisingly, given the availability of lung-cancer-specific chemotherapy, there are no recent studies which use Gc monotherapy as a treatment for lung cancer. All the studies discussed in this review delineate the effects of Gc monotherapy on patients with different manifestations of lung inflammation, a possible precursor to lung cancer. In these cases, monotherapy has little effect although some studies show a slight decrease in lung nodule growth.

There is overwhelming evidence from pre-clinical studies that Gcs, when used as co-treatment during chemotherapy for lung cancers, interfere with
chemotherapy action, promoting growth by preventing death signalling. The ability of Gc co-therapy to interfere with chemotherapy has been attributed to a number of different actions such as enhancing the resistance of cancer cells to chemotherapy-induced apoptosis by inhibition of key pro-apoptotic and upregulation of anti-apoptotic molecules (Herr et al. 2003) or activation of pro-survival Stat5 (STAT5A)/Bcl-xL (BCL2L1) pathways (Qian et al. 2009). Again, sufficient GR levels are necessary and the presence of p53 may play a role in mediating these Gc effects. In xenograft models, Gc pre-treatment prior to chemotherapy at very high doses was shown to enhance chemotherapeutic effects, possibly through its haemoprotective action. Two clinical trials also demonstrate that Gc pre-treatment may have beneficial effects by reducing haematological toxicity. Although older clinical studies and many pre-clinical studies suggest that Gc co-treatment during chemotherapy has a deleterious effect, Gcs are administered routinely as part of the chemotherapy regimen.

It is interesting that Gc monotherapy causes growth arrest but, in the presence of chemotherapy-induced apoptosis, acts in a variety of ways to protect against apoptosis. Both of these actions, described beautifully in vitro and in xenografts, however, depend on the presence of sufficient GR levels and partly on the presence of functional p53, both of which are highly variable in the in vivo situation.

Recent work has shown that the GR is a TSG for lung cancer, with unliganded GR playing an important role in chromosome segregation during mitosis. Loss of the GR, therefore, can result in transformation.

It is therefore possible that the deleterious effects of Gc administration shown in vitro and in xenografts, where the GR content and p53 status are known, may not translate to the clinical setting where genetic heterogeneity exists and GR and p53 status do not play a role in patient stratification. Furthermore, GR downregulation as part of the tumourigenic process may leave the cancers less likely to respond to its effects, and allow other tissues with normal GR content to respond appropriately.

Declaration of interest
There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by a National Research Foundation grant (CSUR13091641336).

References


Qian YH, Xiao Q, Chen H & Xu J 2009 Dexamethasone inhibits camptothecin-induced apoptosis in C6-glioma via activation of...


Turner JD & Muller CP 2005 Structure of the glucocorticoid receptor (NR3C1) gene 5′ untranslated region: identification, and tissue distribution of multiple new human exon 1. Journal of Molecular Endocrinology 35 283–292. (doi:10.1677/jme.1.01822)


Received in final form 7 January 2016
Accepted 21 January 2016
Accepted Preprint published online 21 January 2016